GenHealth.ai Launches AI-Powered Order Automation Solution for Home and Durable Medical Equipment (HME / DME) Providers
Revolutionizing DME Operations: Seamless Automation from Intake to Billing
BOSTON, MASSACHUSETTS / ACCESS Newswire / June 4, 2025 / GenHealth.ai today announced the launch of its AI-powered automation solution specially designed for Durable Medical Equipment (DME) and Home Medical Equipment (HME) providers, helping relieve the burden of complex workflows such as medical order intake, eligibility verification, and prior authorizations. This launch marks a major expansion of GenHealth.ai 's mission to bring intelligent, scalable automation to healthcare operations-boosting accuracy, reducing delays, and accelerating access to care.
Developed in close partnership with early DME customers, GenHealth.ai 's platform streamlines the medical order lifecycle using new advancements in AI and Large Language Models (LMMs)-combined with deep integrations into existing EMR and billing systems-specifically for DME and HME providers.
Key capabilities include:
Early Results: Less Manual Work. Higher Accuracy
Across early implementations, GenHealth.ai has delivered:
'With AI, customers are able to bring on our AI agent to help their existing teams process more cases and increase revenue while reducing administrative costs.' said Ethan Siegel, CPO. Ricky Sahu, CEO, added 'DME providers deserve tools that reduce friction across every step of the order process-and they shouldn't have to rip out their systems to make it work. Our AI integrates into existing customer apps without disrupting how their teams work today.'
Expanding the Vision for Smarter Healthcare Operations
In addition to the DME solution, GenHealth.ai has developed a prior authorization automation solution for providers, designed to accelerate access to high-cost therapies such as GLP-1s and chemotherapies. By combining AI, patient charts, and payer-specific coverage logic, the platform helps providers achieve faster patient-centered approvals-resulting in higher approval rates.
GenHealth.ai will be showcasing these capabilities live at the VGM Heartland Conference in Waterloo, IA, on June 10-11, 2025 and at ENDO 2025 in San Francisco, CA, on July 12-14, 2025.
About GenHealth.ai
GenHealth.ai is a healthcare automation company building AI-powered infrastructure for modern care delivery. The company's platform uses a proprietary Large Medical Model (LMM) to understand real-world clinical data, payer requirements, and operational workflows. GenHealth.ai helps providers, DME suppliers, and care teams reduce administrative burden, improve accuracy, and accelerate patient access to care-all through intelligent, end-to-end automation.
To learn more, contact [email protected] or visit www.genhealth.ai
Contact Information
Mike Maseda
Head of Operations
[email protected]
SOURCE: Genhealth AI
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
19 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Indianapolis Star
a day ago
- Indianapolis Star
Divorced and Facing IRS Collection? Clear Start Tax Outlines How Innocent Spouse Relief Could Save You Thousands
Clear Start Tax Explains How Divorced Taxpayers Can Escape IRS Liability for a Former Spouse's Mistakes IRVINE, CA / ACCESS Newswire Divorce can be complicated enough without the added stress of IRS debt. Yet every year, countless divorced Americans are shocked to discover they're on the hook for a former spouse's tax liabilities – often for mistakes they didn't know about. According to Clear Start Tax, a leading national tax resolution firm, the IRS's Innocent Spouse Relief program can offer a powerful – and often overlooked – solution. When Divorce Leaves Taxpayers Facing a Former Spouse's Mistakes Many taxpayers assume that a divorce decree automatically separates their financial obligations. But under joint tax returns, the IRS can pursue either spouse for the full amount owed, including taxes, penalties, and interest. That means years after a divorce, one spouse may face wage garnishment, bank levies, or collection notices for a tax bill they had no role in creating. 'We've worked with clients blindsided by IRS letters years after their divorce,' said the Head of Client Solutions at Clear Start Tax. 'Innocent Spouse Relief can be a lifeline in these cases – but most people don't even realize it exists.' Who Qualifies for Innocent Spouse Relief? Clear Start Tax explains that the IRS looks at several key factors when reviewing Innocent Spouse claims: The tax understatement was due to the other spouse's error (such as unreported income or inflated deductions). The innocent spouse didn't know, and had no reason to know, about the issue at the time. Holding the innocent spouse liable would be unfair or create hardship. The innocent spouse applies within the IRS's filing window (generally two years from first collection notice). Why the Right Approach Is Essential for Approval While the program offers powerful protection, Clear Start Tax emphasizes that success depends on a careful application and thorough documentation. Missing deadlines, submitting incomplete paperwork, or misunderstanding eligibility rules can lead to denial, leaving taxpayers exposed to the full debt. 'Innocent Spouse Relief isn't just a form-it's a carefully built case,' said the Head of Client Solutions at Clear Start Tax. 'We work closely with our clients to present the strongest possible application, so they can move forward without being burdened by a former partner's tax mistakes.' How Clear Start Tax Helps Divorced Taxpayers Regain Control Clear Start Tax offers a hands-on, strategic approach to Innocent Spouse claims and other tax resolution programs: Comprehensive case reviews to assess eligibility and strengthen claims Detailed preparation of IRS applications with supporting evidence Direct IRS communication and negotiation on the client's behalf Post-resolution guidance to maintain compliance and peace of mind About Clear Start Tax Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm's unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry. Need Help With Back Taxes? Click the link below: Contact Information Clear Start Tax Corporate Communications Department seo@ (949) 535-1627 SOURCE: Clear Start Tax View the original press release on ACCESS Newswire
Associated Press
a day ago
- Associated Press
Torq Completes $3.12 Million Recapitalization Transactions
NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISTRIBUTION INTO THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / June 6, 2025 / Torq Resources Inc. (TSXV:TORQ)(OTCQB:TRBMF) ('Torq' or the 'Company') is pleased to announce that, further to its March 24, 2025 news release, it has completed its previously announced private placement, by issuing 25,152,633 units of the Company (each, a 'Unit') at an offering price of $0.06 per Unit for gross proceeds of C$1,509,158 (the 'Offering'). Each Unit consists of one common share (a 'Share') and a Share purchase warrant (each, a 'Warrant') exercisable until June 6, 2027 to acquire a Share for C$0.12. The Warrants are subject to an accelerated expiry if, anytime following the date that is four months after the Closing Date, the closing price of the common shares of the Company on the TSXV, or such other market as the common shares may trade from time to time, is or exceeds $0.30 for any 10 consecutive trading days, in which event the holder of the Warrants may, at the Company's election, be given notice and the Company will issue a press release announcing that the financing Warrants will expire 30 days following the date of such press release. The Offering Warrants may be exercised by the holder of the Warrant during the 30-day period after the date of the press release announcing the accelerated expiry date. The placement proceeds from the Offering will be used for working capital. In addition, the Company has issued 1,998,829 Shares to non-arm's length creditors and 19,619,394 Units (identical to those in the Offering) to arm's length creditors to settle an aggregate of $1,297,093.60 of debts (the 'Debt Settlement'). The debts relate primarily to the 2024 Minera Santa Drilling Campaign and also include $310,000 which was advanced and spent pursuant to the previous private placement financing, announced on October 2, 2024 and November 18, 2024, which did not complete. In connection with the closing of the Offering, the Company paid cash finder's fees of $51,012 and issued 800,200 non-transferable one-year finder's warrants. Each finder's warrant will entitle the holder thereof to purchase one common share of the Company at the exercise price of C$0.06 until June 6, 2026. Each finder's warrant is also subject to the accelerated expiry as described above. The Company is continuing to seek regulatory approval for the extension of its credit facility for a further one-year period until July 11, 2026. In accordance with applicable securities laws, the securities issued under the Offering and Debt Settlement are subject to a statutory four-month and one-day hold period from the date of issuance in Canada. There was no insider participation in the Offering. 1,998,829 shares were issued to non-arm's length creditors in the Debt Settlement. The Company will be relying on the exemption from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(a) and 5.7(1)(a) of Canadian Multilateral Instrument 61-101 - Protection of Minority Shareholders in Related Party Transactions, as neither the fair market value of any securities issued to nor the consideration paid by such person could exceed $2.5 million or 25% of the Company's market capitalization. None of these securities will be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any U.S. state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act and all applicable state securities laws or else in compliance with the requirements of an applicable exemption therefrom. A Message from Shawn Wallace, CEO: 'The Offering and Debt Settlement transactions greatly improve our financial position and should provide the impetus for a more active 2025. We are looking forward to the receipt of assays on the Santa Cecilia project where exploration funding is being provided by Gold Fields under an earn-in option.' ON BEHALF OF THE BOARD, Shawn Wallace CEO & Chair For further information on Torq Resources, please visit or contact the company at (778) 729-0500 or [email protected]. About Torq Resources Torq is a Vancouver-based copper and gold exploration company with a portfolio of premium holdings in Chile. The Company is establishing itself as a leader of new exploration in prominent mining belts, guided by responsible, respectful and sustainable practices. The Company was built by a management team with prior success in monetizing exploration assets and its specialized technical team is recognized for their extensive experience working with major mining companies, supported by robust safety standards and technical proficiency. The technical team includes Chile-based geologists with invaluable local expertise and a noteworthy track record for major discovery in the country. Torq is committed to operating at the highest standards of applicable environmental, social and governance practices in the pursuit of a landmark discovery. For more information, visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Torq Resources Inc. press release
